GCMG · GCM Grosvenor Inc.

The thesis

GCM Grosvenor's recurring-fee growth still argues for a higher share price than the $12.53 close of 5 November 2026. The third-quarter report on 9 November 2026 settles it by showing whether reported fee-related earnings keep growing and fundraising holds at or above the second quarter's $2.3 billion.

The narrative is maturing: the 10 August 2026 second-quarter report is still the latest earnings disclosure, and the main company news since the last update is the 28 October 2026 expansion of the Proteus MHP real-estate partnership. The shares rose from $12.22 on 28 October 2026 to $12.53 on 5 November 2026 (adjusted daily closes), with no results behind the move.

Fee-related earnings (FRE) are the profit from management and advisory fees, before performance income. Second-quarter reported FRE was $50.3 million, up from $41.6 million a year earlier, at a 45% margin (company 8-K, 10 August 2026). The published five-analyst average target is $14.88 (StockAnalysis, read 5 November 2026), so analysts already price in growth that the report has to confirm.

Bullish and bearish views on GCM Grosvenor Inc.

The bull case on GCM Grosvenor Inc. (GCMG), in brief: Fee earnings grew faster than revenue. The bear case: Analysts lowered targets into the report.

Bull case

• Fee earnings grew faster than revenue. Second-quarter FRE rose 21% against 11% growth in fee-related revenue of $111 million, and the FRE margin reached 45% versus 31% in 2020 (company results release, 10 August 2026).
• Management said on the 10 August 2026 call that it expects second-half 2026 fundraising to exceed the first half.
• Credit brings in fee-paying capital. Credit contributed more than $900 million of the $2.3 billion raised in the second quarter (10 August 2026 call). The inaugural Credit Secondaries Fund closed at $1.2 billion on 23 July 2026.
• Real-estate partnerships are getting larger. Proteus MHP said on 28 October 2026 that GCM Grosvenor's real estate practice raised its investment to about $145 million, with a goal of about $400 million in portfolio assets (press release relayed by Quantisnow). The original commitment announced in June 2025 was $60 million.
• Analyst targets sit above the price. StockAnalysis shows a $14.88 average and a $13 to $16 range across five analysts, read 5 November 2026. TD Cowen reiterated $16 on 12 August 2026, and William Blair kept a positive rating on 5 October 2026.

Bear case

• Analysts lowered targets into the report. StockAnalysis lists Piper Sandler's 19 October 2026 cut as $16 to $15, while an earlier report gave $14.50. Oppenheimer cut to $16 from $17 on 20 October 2026. Both firms kept positive ratings.
• Full-year estimates imply much slower growth. StockAnalysis shows 2026 consensus revenue of $583.91 million, up 5.33%, and adjusted earnings per share of $0.90, up 6.9%. Both sit well below the 21% FRE growth reported for the second quarter.
• The reported acceleration may fade. The 21% FRE increase compares against a prior-year period that carried catch-up fees, so the growth rate can revert when that comparison rolls off.
• Accounting profit lags fee profit. Net income under US accounting standards (GAAP) was $9.6 million in the second quarter, down 38% from a year earlier (10 August 2026 filing).
• Insiders and holders sold in 2026. Form 4 summaries on Quantisnow show Cantor Fitzgerald selling 557,106 units at $13.63 in mid-July, Kathleen Sullivan 40,000 at $13.16 around 3 September 2026, and Chief Financial Officer Pamela Bentley 50,000 at $12.59 in mid-September under a pre-agreed plan. Each price is above or near the latest close.
• One major firm sits near the price. J.P. Morgan keeps a neutral rating with a $13 target, raised from $12 on 11 August 2026 (StockAnalysis).

Price setup

The shares closed at $12.53 on 5 November 2026, 10.1% below the 52-week high of $13.93 and down 8.5% over three months (adjusted daily closes). The relative strength index, a 14-day momentum gauge on a 0 to 100 scale, stands at 49.5, up from 36.3 on 28 October 2026. That reading is close to neutral.

The closest dated support is the 200-day moving average of $11.71 reported on 5 September 2026 (MarketBeat). On that reading the shares trade less than a dollar above the average, so there is no wide gap to unwind.

Observable crowding is modest. The earnings date is one session away, and insider sales arrived between mid-July and mid-September at prices from $12.59 to $13.63. Insiders hold 70.70% of Class A shares (MarketBeat, 5 September 2026), which leaves a thin float. Research turned up no evidence of heavy retail attention, and Quantisnow's company feed shows no headline dated November as of 5 November 2026.

Catalysts, next 30 days

• 9 November 2026: third-quarter 2026 results and 9:00 a.m. Eastern call (company announcement, 26 October 2026). FXEmpire cites five-analyst estimates of $0.21 in earnings per share and $146.13 million in revenue, while Earnings Whispers shows $154 million in revenue.
• ~9 November 2026, est.: quarterly report on Form 10-Q. The second-quarter 10-Q arrived with the results. It shows GAAP net income and performance-income detail against the $9.6 million reported for the second quarter.
• ~9 November 2026, est.: next dividend decision. The prior $0.12 dividend, payable 15 September 2026, was announced with second-quarter results (Quantisnow).

What would change the view

Flat or declining year-over-year reported FRE in the 9 November 2026 report would break the case, because recurring-fee growth is the whole argument. Third-quarter fundraising below the second quarter's $2.3 billion, or fee-paying AUM growth slowing from about 13%, would undercut management's expectation that the second half exceeds the first.

Reported FRE growth in the low single digits would point to the second-quarter 21% as mostly a comparison effect and weaken the case without ending it. Further target cuts after the report, on top of the October cuts by Piper Sandler and Oppenheimer, would show analysts losing confidence in it.

On price, a weekly close below $11.50, under the $11.71 200-day moving average reported on 5 September 2026, would end the thesis. A weekly close above the $13.93 52-week high would show buyers accepting the fee growth.

What it trades with

No measured correlation figure is available for this note. The drivers disclosed by the company point to alternative-asset fundraising as the main shared exposure, with credit at more than $900 million of second-quarter fundraising and real estate supplying the recent partnership news.

The view here is that the 9 November 2026 report outweighs moves in peer stocks in the coming sessions, helped by the thin Class A float. A share-price drop on FRE growth and fundraising at or above $2.3 billion would show that sector sentiment is the stronger force.